Introduction
The efflux transporter P-glycoprotein (P-gp) attenuates the CNS distribution of many drugs, including opioids, triptans, protease inhibitors, and antihistamines. One method used to assess the influence of P-gp on the CNS distribution of compounds is the P-gp-deficient mouse model.
The P-gp efflux ratio, calculated from the ratio of brain-to-plasma partition coefficient (K p,brain ) in P-gp-deficient (mdr1a-/-) mice to K p,brain in P-gp-competent (mdr1a+/+) mice, reflects the degree to which P-gp-mediated efflux attenuates CNS distribution. However, when other processes influence CNS distribution, the P-gp efflux ratio may be a poor indicator of the degree to which CNS distribution of a compound is impaired.
K p,brain is the most widely used in vivo parameter for assessing the extent of CNS distribution.
A common assumption is that compounds with large K p,brain values have more extensive CNS distribution than compounds with small K p,brain values. For example, a K p,brain ≥ 1 is often used as an arbitrary cutoff to classify compounds as having "good" CNS distribution, while a K p,brain <<1 is used to classify compounds as having "poor" CNS distribution. While this type of classification is common, it may be misleading. It is recognized that tissue partition coefficients such as K p,brain are influenced by the relative binding affinity of a substrate for proteins in plasma versus the proteins in the tissue in question (Gillette, 1971; Kurz and Fichtl, 1983) . For a compound that distributes solely by passive diffusion, at distribution equilibrium the unbound concentration in tissue will equal the unbound concentration in plasma, and the steady-state tissue partition coefficient is simply a function of the relative plasma and tissue unbound fractions (i.e., K p,tissue = f u,plasma / f u,tissue ). When brain and plasma unbound fractions are similar, than a K p,brain ~1 would be consistent with unrestricted distribution solely by passive processes.
However, the K p,brain value by itself provides little information without knowledge of brain and This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on January 19, 2007 as DOI: 10.1124 at ASPET Journals on November 6, 2017 dmd.aspetjournals.org Downloaded from plasma unbound fractions. A K p,brain value <1 could be the result of more extensive binding to plasma proteins than to proteins in brain tissue. Alternatively, a K p,brain value <1 it could reflect significant impairment in CNS distribution due to processes such as efflux transport at the bloodbrain barrier (BBB).
Several recent literature reports have utilized the f u,plasma /f u,brain ratio to predict K p,brain and to assess the CNS distribution of compounds. In one published account, the utility of the f u,plasma /f u,brain ratio to predict the K p,brain of CNS discovery compounds was assessed (Kalvass and Maurer, 2002) . As expected, the f u,plasma /f u,brain ratio predicted the K p,brain for compounds that did not evidence active efflux at the BBB, and over-predicted K p,brain when active efflux at the BBB limited brain uptake. The degree to which the f u,plasma /f u,brain ratio over-predicted K p,brain was identical to the P-gp efflux ratio for the single member of the compound set for which the P-gp efflux ratio had been determined. Another study used the f u,plasma /f u,brain ratio to predict K p,brain and to assess the CNS distribution of 33 marketed CNS drugs (Maurer et al., 2004) . The f u,plasma /f u,brain ratio predicted the K p,brain value for the majority of CNS drugs (25 of 33), indicating that most CNS drugs do not have impaired CNS distribution. In those cases for which the f u,plasma /f u,brain ratio did not predict K p,brain , the discrepancy could be explained by active efflux or poor BBB permeability. More recently, for compounds subject to active efflux, the f u,plasma /f u,brain ratio combined with in vitro efflux data was shown to provide superior estimates of K p,brain as compared to the f u,plasma /f u,brain ratio alone (Summerfield et al., 2005) .
When CNS distribution is impaired, the f u,plasma /f u,brain ratio over-predicts K p,brain . The magnitude of the over-prediction is reflective of the degree to which unbound plasma concentrations exceed unbound brain concentrations (eq. 1).
This article has not been copyedited and formatted. The final version may differ from this version. protease inhibitors, and antihistamines (n = 24 total) were included in this analysis because these classes of agents are known to include P-gp substrates, and the extent to which these compounds distribute into the CNS may have important implications regarding safety and efficacy. In addition, 10 marketed drugs from various drug classes with either poor CNS distribution or BBB efflux also were included as part of the analysis.
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Drug Selection. Twenty-four marketed drugs from four main drug classes (7 opioids, 5 triptans, 5 protease inhibitors, and 7 antihistamines) were chosen for this study because drugs within each class exhibit varying degrees of interaction with BBB P-gp and because the extent of CNS distribution is known to be important to the efficacy and/or toxicity of these drug classes.
In addition, 10 marketed drugs from other drug classes with either poor CNS distribution or BBB efflux also were chosen to assess the general utility of the approach with as diverse a dataset as possible. Equilibrium dialysis experiments. Plasma and brain unbound fractions were determined in a 96-well equilibrium dialysis apparatus (HTDialysis, Gales Ferry, CT) using a previously reported method (Kalvass and Maurer, 2002) . Briefly, fresh CF-1 or FVB mouse plasma and brain tissue were obtained the day of the study. Spectra-Por 2 membranes obtained from for 15 min. Brain tissue was diluted 3-fold with 100 mM sodium phosphate buffer (pH 7.4) and homogenized with a sonic probe. The drug of interest was added to plasma and brain homogenate to achieve a final concentration of 3 and 1 µ M, respectively; 150-µl aliquots (n=6) were loaded into the 96-well equilibrium dialysis apparatus and dialyzed against and equal volume of 100 mM sodium phosphate (pH 7.4) buffer. The 96-well equilibrium dialysis apparatus was incubated for 4.5 hr in a 155 rpm shaking water bath maintained at 37˚C. Prior experience with the equilibrium dialysis apparatus indicated that equilibrium would be achieved by 4.5 hr (data not shown). After 4.5 hr, 10 µ l of matrix sample (plasma or brain homogenate)
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and 50 µ l of buffer sample were removed from the apparatus and added directly to HPLC vials containing 100 µl of methanol containing an appropriate internal standard. A 50-µl aliquot of control buffer was added to the brain homogenate and plasma samples, and either a 10-µl aliquot of control brain homogenate or control plasma was added to the buffer samples to yield identical sample composition between buffer and non-buffer samples. The samples were vortex-mixed, centrifuged, and the supernatant was analyzed by HPLC-MS/MS. Plasma unbound fraction was calculated from the ratio of concentrations determined from the plasma and buffer samples.
Equation 2, a previously described approach to account for the effect of tissue dilution on unbound fraction (Kalvass and Maurer, 2002) , was used to calculate the brain unbound fraction: (Table 1) . During the run, the flow rate was increased from 750 to 1500 µl/min over the first 2 min, held at 1500 µl/min for 1 min, and then returned to the initial flow rate of 750 µl/min in a single step. For samples run on the API3000, the flow rate was increased from 500 to750 µl/min over the first 2 min, held at 750 µl/min for 1 min, and then returned to the initial flow rate of 500 µl/min in a single step. The entire column effluent was diverted from the source of the quadrupole mass spectrometer for the first 0.8 min and final 0.5 min of the run. Standards were prepared with either plasma or brain have been shown to have P-gp efflux ratios <3 (Doran et al., 2005) . The figure was divided into four quadrants (I-IV) based on whether the P-gp efflux or [plasma] ,u /[brain] ,u ratio values were greater than or less than 3. The solid line passing through the origin represents the line of identity ± 3-fold (dashed lines). Drugs were assessed as follows: quadrant I-impaired CNS distribution due to P-gp-mediated efflux; subsections Ia and Ib-impaired CNS distribution due to P-gp with other active process(es) present; quadrant II-impaired CNS distribution due to non-Pgp mechanism; quadrant III-no impairment in CNS distribution; quadrant IV-P-gp substrate, but CNS distribution is not impaired due to the presence of a compensatory mechanism. The CNS distribution behavior of the protease inhibitors, opioids, antihistamines, and triptans were evaluated separately.
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Results
The K p,brain , f u,plasma , and f u,brain values for all drugs included in this study are reported in Table   2 . The K p,brain and f u,brain values varied by more than 4 orders of magnitude, whereas the f u,plasma values varied by more than 3 orders of magnitude, among the drugs studied. Vinblastine was unstable in mouse plasma, so the f u,plasma value was reported as equal to or greater than the f u,plasma value determined from the buffer concentrations, assuming complete mass balance. This article has not been copyedited and formatted. The final version may differ from this version. between the different triptans. By understanding the inter-relationships between in vivo efficacy, incidence of CNS side-effects, and the extent of CNS distribution, the optimal CNS distributional characteristics of triptans may be deduced.
Protease Inhibitors. All of the protease inhibitors examined undergo significant P-gp efflux (P-gp efflux ratio ≥ 7, quadrant I and IV). However, the [plasma] ,u /[brain] ,u ratio indicated that ritonavir and saquinavir, despite being P-gp substrates, do not have impaired CNS distribution (< 3-fold). This observation may be explained if a compensatory mechanism (i.e., active uptake)
negates the impact of P-gp-mediated efflux. This explanation is supported by reports demonstrating that both ritonavir and saquinavir are substrates for uptake transporters (Anthonypillai et al., 2004; Su et al., 2004) .
Even though it has been thought that ritonavir and saquinavir have poor CNS distribution because of significant P-gp-mediated efflux (in vivo P-gp efflux ratio > 5) and low K Antihistamines. Consistent with their central activity, the sedating antihistamines triprolidine, diphenhydramine, and hydroxyzine had minimal impairment in CNS distribution (quadrant III).
The non-sedating histamines desloratadine and cetirizine fell within quadrants I and Ib, respectively, indicating substantial impairment in CNS distribution due to P-gp-mediated efflux.
However, the P-gp efflux ratio did not indicate impairment in CNS distribution of the non- Other drugs with poor CNS distribution or BBB efflux. Other marketed drugs with poor CNS distribution or BBB efflux were examined along with the opioids, triptans, protease inhibitors, and antihistamines ( Figure 3 ). As expected, P-gp substrates such as quinidine, verapamil, and paclitaxel fell within quadrant I (consistent with P-gp being the only efflux mechanism), while efflux substrates for transporters other than P-gp such as ranitidine, digoxin, and doxorubicin fell within quadrants Ib and II ( Figure 3 and Table 3 ).
Discrepancy between P-gp efflux ratio and the [plasma] ,u /[brain]
,u ratio. The P-gp efflux ratio and the [plasma] ,u /[brain] ,u ratio differed by more than 3-fold for 13 of the 34 drugs examined. In most cases, the difference can be explained by the physiochemical properties, and/or transport characteristics of the individual drugs (Table 3) . Ten of the 13 drugs for which discrepancy was noted were located in either quadrant Ib or II, indicating more extensive This article has not been copyedited and formatted. The final version may differ from this version. impairment in CNS distribution than predicted by the P-gp efflux ratio. For these 10 drugs, six drugs (digoxin, doxorubicin, ivermectin, cimetidine, dexamethasone, and ranitidine) are known to be substrates for efflux transporters other than P-gp (Table 3) , two (sumatriptan and zolmitriptan) have very low permeability values (less than mannitol), and two (cetirizine and fexofenadine) have reduced central activity relative to other drugs in the same class. The remaining three of the 13 drugs (methadone, ritonavir, and saquinavir) for which the P-gp efflux ratio and the [plasma] ,u /[brain] ,u ratio differed by more than 3-fold were classified in quadrant IV, indicating less impairment in CNS distribution than indicated by the P-gp efflux ratio. One possible explanation for such drugs is the presence of a compensatory active uptake mechanism.
Consistent with this explanation, all three of these drugs are substrates of active uptake (Table 3) .
Although not the intent of this work, additional detailed studies on individual drugs would be useful to confirm whether the discrepancy between the P-gp efflux ratio and the This article has not been copyedited and formatted. The final version may differ from this version. drugs. The CNS distributional behavior of each drug was assessed according to the scheme in Figure 1 . As expected, P-gp substrates such as quinidine, verapamil, and paclitaxel fell within quadrant I (consistent with P-gp being the only efflux mechanism), while drugs subject to transport by other transporters or with poor BBB permeability, such as ranitidine, digoxin, and doxorubicin fell within quadrants Ib, II, or IV. Symbols for drugs are defined in Table 2 .
This article has not been copyedited and formatted. The final version may differ from this version. Figure 1 . Additional evidence from the literature is provided to support of classification of each drug.
Class Ib P-gp efflux + additional mechanism
